Dawn of China biopharma innovation

Having invented the concept, it is odd that China should have been so behind in making medicine for so long. That has changed: the Chinese pharmaceutical market is now the second biggest in the world, and for many years the Chinese state has been driving towards the enormous opportunities that a firmer grip on this drug development could bring, according to a report from McKinsey & Co.

China’s biopharmaceutical ecosystem is experiencing a momentous shift from a formerly generics-focused play into one that nurtures innovation, with profound implications for patients and industry peers.

In this report, McKinsey, takes the pulse of China’s vibrant innovation ecosystem, looks at the key trends driving the biopharma industry, and shares thoughts on how multinational pharmaceutical players can tap into innovation opportunities in the world’s second-largest healthcare market.